-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 29, Simcere Pharmaceuticals and Vivoryon Therapeutics jointly announced that the two parties have established a strategic regional licensing cooperation to develop and commercialize Alzheimer’s targeting neurotoxic amyloid N3pE (pGlu-Aβ) in Greater China.
According to the agreement, Simcere Pharmaceuticals will be permitted to develop and commercialize two AD drugs developed by Vivoryon in the Greater China region.
Among them, varoglutamstat is an oral small molecule inhibitor of glutamyl peptide cyclase (QPCT)
PBD-C06 is a humanized, deimmunized IgG1 antibody drug in the pre-clinical development stage.
Note: The original text has been deleted